Stacy Ann Coen
CIK: 0001814150
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
FBLG
FibroBiologics, Inc.
Director
Discretionary Trading P&L
Holdings
About Coen Stacy Ann
Coen Stacy Ann (SEC CIK 0001814150) files insider reports with the SEC as Director of FibroBiologics, Inc. (FBLG).
Signal8 holds 1 ownership filing by Coen Stacy Ann, a Form 4, filed on Jun 12, 2025. Those filings report 1 transaction, the latest on Jun 12, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Coen Stacy Ann's filings is in HOUSTON, TX.
Recent filings by Coen Stacy Ann
- Jun 12, 2025: Grant or award of FBLG derivative securities (Form 4, code A).
Other insiders filing for FibroBiologics, Inc. (FBLG)
- Khoja Hamid, Chief Scientific Officer
- Steinberg Leigh, Director
- Rubins Kathleen Hallisey, Director
- Hoffman Robert E., Director
- Cilento Richard C. Jr., Director
- Link Matthew, Director